Effortil

Etilefrine

Method of action: Cardiac Therapy

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Effortil

Property	Description
Active ingredient	Etilefrine (Etilefrine hydrochloride)
Form	Tablets, oral drops, injectable solution
Pharmacological class	Sympathomimetic agent, Antihypotensive agent
General purpose	Elevating low blood pressure (hypotension)
Origin	Synthetic substituted phenethylamine derivative

What is Effortil and What Type of Medicine is It?

Effortil is a pharmaceutical product centrally identified as an antihypotensive agent, a medication specifically utilized to elevate and stabilize pathologically low blood pressure, known as hypotension. The drug's primary classification is a sympathomimetic agent, meaning it acts upon the sympathetic nervous system to reinforce the body's natural circulatory reflexes. Etilefrine is cataloged under the code C01CA01, designating it among the heart stimulating agents. The oral drops formulation, in particular, offers a differentiating feature by allowing flexible dosing for chronic hypotensive dysregulation, a characteristic recognized for managing positional faintness.

Composition and Physiological Action

The therapeutic effect of Effortil derives from its single active ingredient, Etilefrine, usually supplied as the Etilefrine hydrochloride salt. Etilefrine is a synthetic substituted phenethylamine derivative, a small molecule sharing a foundational chemical structure with endogenous catecholamines. As a monocomponent product, Effortil contains no other primary active substances. Etilefrine acts to increase both heart contractility and venous tone. This action helps the heart pump more effectively and assists in tightening blood vessels.

The general purpose of Effortil is to provide relief from symptoms associated with poor circulation and low blood pressure by exerting a controlled pressure-raising effect. The availability in three distinct drug forms—oral tablets, oral drops, and sterile injectable solution—is a crucial differentiating factor, allowing it to address both chronic, non-urgent hypotensive states and conditions requiring immediate circulatory support. This versatility ensures that an effective amount of Etilefrine can be delivered for the purpose of maintaining proper organ perfusion.

What side effects are possible with Effortil?

Possible Side Effects and Safety Information

The safety profile for Effortil (Etilefrine) is formally documented in regulatory prescribing information, classifying potential adverse reactions by the physiological system affected and the frequency of occurrence.

Adverse Reaction Classification

Side effects are categorized by frequency, reflecting official regulatory data. Headache and a sensation of pressure in the head are listed as common adverse reactions. Reactions classified as uncommon include effects such as dizziness, tremor, restlessness, anxiety, and insomnia. The sympathomimetic action is reflected in uncommon effects on the heart, including tachycardia (increased heart rate), palpitations, and cardiac arrhythmia. A serious allergic reaction (hypersensitivity) is also documented in regulatory sources, though the frequency is noted as not known.

System-Organ Class	Common Adverse Reactions	Uncommon Adverse Reactions
Nervous System	Headache	Dizziness, Tremor, Sensation of pressure in the head
Cardiac/Psychiatric	–	Tachycardia, Palpitations, Anxiety, Restlessness, Insomnia

Safety Restrictions and Special Populations

Official labeling defines several limitations and constraints for the use of Effortil. The medication is strictly contraindicated (prohibited) in patients with pre-existing conditions such as hypertension (high blood pressure), uncontrolled thyrotoxicosis (overactive thyroid), specific coronary heart conditions (e.g., coronary heart failure), and phaeochromocytoma. Furthermore, the drug is contraindicated during the first trimester of pregnancy and throughout breastfeeding. Safety documentation also notes that the substance can result in positive results in athlete doping tests and advises caution for individuals with diabetes or severe cardiovascular disorders.

Overdose and Emergency Response

Effortil overdosage is officially documented as an acute intensification of the drug’s pharmacological effects, primarily impacting the cardiovascular and central nervous systems. Clinical manifestations described in regulatory documents include a cluster of symptoms such as significantly increased blood pressure (hypertension), palpitations, tachycardia, tremor, headache, anxiety, and agitation.

When to Seek Immediate Help

The official guidance mandates that individuals must seek immediate medical attention upon the suspicion or confirmation of an acute overdosage. Regulators further state that intensive care measures should be implemented in cases classified as severe.

Severe and Population-Specific Risks

Overdose may lead to severe systemic outcomes such as hyperthermia and potential rhabdomyolysis. A specific, life-threatening risk is noted for the pediatric population: in babies and small children, overdosage has been documented to cause central respiratory paralysis and coma.

Official Management Strategies

Overdose management is centered on providing symptomatic and supportive treatment. No specific antidote is officially known. Treatment procedures described in regulatory labeling include the use of pharmacological agents, such as beta-blockers or parenteral antihypertensives, to counteract the exaggerated cardiovascular effects. Procedural measures such as gastric lavage and the administration of activated charcoal are also noted as potential options.

Therapeutic Uses of Effortil

What Effortil Treats: Main Uses and Benefits

Effortil is a medication generally used to manage symptoms related to hypotension (low blood pressure) and is considered relevant for maintaining functional stability. The core therapeutic focus addresses symptoms related to systemic imbalance and associated patient discomfort. Its therapeutic indications include helping manage hypotension in various forms.

Symptom Relief and Clinical Scenarios

The medication is applicable across domains where additional symptomatic support is needed. It is commonly used to help address clusters of symptoms that interfere with daily functioning, such as dizziness, lightheadedness, and a tendency to faint (presyncope), particularly those linked to orthostatic hypotension (drops in pressure upon standing). Effortil may also assist with generalized weakness and persistent fatigue associated with chronic low pressure, and it is relevant in clinical settings for managing severe blood pressure drops during procedures like anaesthesia or in cases of circulatory failure.

It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

“It supports patients during difficult episodes by easing distress.”

Quick Fact: Relief for Positional Symptoms
Effortil is commonly used to help manage the pronounced symptoms that are triggered or worsened by changes in body position.

Regulatory References

Approved Professional Information for Effortil (South Africa)

Eligibility and Restrictions for Use

Who Can and Cannot Use Effortil?

Effortil (Etilefrine) is strictly limited to certain patient populations and is prohibited for use in individuals with specific pre-existing health conditions, as defined by official regulatory labeling. Use is generally permitted for adults and adolescents 12 years of age and older who are diagnosed with low blood pressure (hypotension).

Absolute Contraindications

The medicine must not be used by individuals with the following conditions:

Hypertension (high blood pressure) or a hypotensive condition that results in a hypertensive response upon standing.
Severe cardiac diseases, including decompensated heart failure, coronary artery disease, and hypertrophic obstructive cardiomyopathy.
Endocrine conditions such as thyrotoxicosis (severe hyperthyroidism) and phaeochromocytoma.
Narrow angle glaucoma or prostatic hypertrophy leading to urinary retention.
Known hypersensitivity to Etilefrine or tablet excipients (e.g., lactose intolerance).

Age and Reproductive Restrictions

Effortil is not recommended for children under 12 years of age. It is contraindicated during the first trimester of pregnancy and must not be used while breastfeeding. Use in the second and third trimesters of pregnancy is restricted and requires careful assessment.

What should I know about interactions with other medicines?

Effortil Interactions with Other Medicines and Products

Effortil (Etilefrine) interacts with other substances primarily through effects on blood pressure and heart function, as documented in official regulatory prescribing information. These interactions are categorized by their effect: reinforcement, antagonism, and specific cardiotoxicity risks.

Documented Interaction Patterns

The following table outlines substances and drug classes that interact with Etilefrine according to regulatory documents:

Interaction Type	Interacting Substances/Classes
Reinforcement of Effect	Thyroid hormones, Mineralocorticoids, Reserpine, Other sympathomimetics (including MAO Inhibitors, Tricyclic Antidepressants), Dihydroergotamine (increases absorption), Atropine.
Increased Arrhythmia Risk	Halogenated aliphatic hydrocarbons (in inhalational anesthetics), Cardiac Glycosides (in higher doses).
Antagonism / Reduced Effect	Adrenergic blocking agents (alpha-blockers and beta-blockers). beta-blockers may also induce reflex bradycardia.
Therapeutic Antagonism	Antidiabetic medication (Effortil may decrease their blood sugar-lowering effect).

Official regulatory sources do not list any combination as formally contraindicated based solely on interaction risk. There are no documented interaction-related timing requirements for co-administration, nor are there explicit cautions regarding interactions with food, alcohol, or herbal products.

Mechanism of Action

How Effortil Works — Mechanism of Action

Effortil (Etilefrine) functions as a sympathomimetic agent by activating specific adrenergic receptors within the cardiovascular system, thereby influencing two key hemodynamic components: the peripheral vasculature and the heart muscle.

Dual alpha1 and beta1 Adrenergic Receptor Agonism

Effortil acts as a direct agonist on Alpha-1 (alpha1) and Beta-1 (beta1) adrenergic receptors. This mechanism engages signaling pathways characteristic of the sympathetic nervous system. The alpha1 agonism drives effects on the blood vessels, while the beta1 agonism influences the heart's function.

Vascular Tone and Venous Return Cascade

Activation of alpha1 receptors on vascular smooth muscle, particularly in the veins, initiates a cascade leading to vasoconstriction. This physiological adjustment reduces the capacity of the veins, shifting blood volume toward the heart. This action affects processes related to peripheral pooling and results in increased venous return.

Modulating Myocardial Contractility and Cardiac Output

Simultaneous activation of beta1 receptors in the heart muscle triggers signaling events that enhance myocardial contractility (the force of contraction). This effect enhances the force of the heart's pumping action, leading to an increase in stroke volume. The resulting physiological consequence is an adjustment in the amount of blood the heart pushes out per minute (cardiac output).

Dosage and Administration Information

How to Use Effortil: Administration Guidelines

Effortil (etilefrine) is used in accordance with standard administration guidelines which govern the correct intake of the medicine. These guidelines define the dose, timing, and preparation requirements for different dosage forms.

Administration Scope

Feature	Standard Practice
Route of Administration	Oral (tablet or drops) or Parenteral (intravenous, intramuscular, or subcutaneous injection).
Timing in Relation to Meals	Doses are generally taken during the day, and preferably before meals.
Preparation Requirements	Oral drops are diluted in a liquid before ingestion.
Special Procedural Conditions	Parenteral forms (injection/infusion) are administered by qualified healthcare professionals.

Dosage and Frequency Rules

Dosing is based on the patient's age and the specific dosage form. The medicine is typically taken multiple times daily.

Adults and Children over 7 years (Tablet): Standard oral dosing typically involves 1–2 tablets (5–10 mg) taken three times daily. The dose may be adjusted based on the patient’s clinical state.
Children 1–7 years (Tablet): Standard oral dosing typically involves 1/2–1 tablet taken three times daily.

Missed Dose Instructions

If a dose is missed, the general practice is to take the dose as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular dosing schedule is continued. Two doses are not taken at the same time.

Recent Clinical Evidence

Effortil: Recent Clinical Evidence

This overview summarizes the type of research that has been conducted on the medicine Etilefrine (Effortil), focusing on the structure of the evidence base according to scientific literature. This information describes patterns observed in groups of patients and does not provide individual medical predictions or advice.

Evidence for use in Orthostatic Hypotension and Associated Symptoms

Research has been conducted using Randomized Controlled Trials (RCTs) and Systematic Reviews, monitoring adults with low blood pressure presenting with symptoms. The research examined both objective hemodynamic measures and patient-reported outcomes related to physical discomfort. Research describes data collected, but analysis indicates that findings are often mixed and heterogeneous across different studies.

What remains uncertain is the full picture of long-term outcomes, as follow-up durations were limited. Evidence quality varies, and there is noted inconsistency in the reported data: studies explored how the medicine was studied in relation to objective blood pressure numbers, but its correlation with patient-reported symptom relief is not fully established.

Evidence for use in Acute Hypotension During Medical Procedures

The injectable form has been studied in Multicenter, Double-Blind RCTs during acute settings like regional anaesthesia for cesarean delivery. Research monitored maternal hemodynamic stability and fetal/neonatal outcomes. Comparative evidence is available, where studies explored performance against other agents used for the same purpose in preventing the initial onset of low blood pressure during the procedures.

Long-Term Studies and Follow-up Durations

Research has explored short-term symptom changes, focusing on the immediate or short-to-intermediate-term response. While the evidence contributes to understanding symptom patterns, the durability of the patterns observed over many months or years is not well characterized. There is limited information for long-term outcomes.

Evidence in Special Populations and Subgroups

Research has explored the use of the medicine across adult populations, including older adults and pregnant women during surgery. Studies monitored responses in these groups, but the available data for certain highly specific subgroups or for children remains insufficient, and results apply only to the populations studied.

What is Still Uncertain About the Research for Effortil

The research base has provided context, but some key limitations exist. Evidence quality varies across studies, and sample sizes were modest in many trials. Methodological heterogeneity is a notable feature. Furthermore, long-term effects are not fully established, and comparative evidence against a non-treatment control (placebo) is limited in some contexts. Research is ongoing to better understand the full range of outcomes related to functional imbalance.

Key Studies & References

The effects of ephedrine and etilefrine on uterine and fetal blood flow and on fetal myocardial function during spinal anaesthesia for caesarean section

Frequently Asked Questions (FAQ)

Common questions about Effortil (FAQ)

Q: How quickly can a person expect Effortil to start working?

Official regulatory documents state that the active ingredient in Effortil is quickly absorbed after being taken by mouth. Based on pharmacokinetic studies, the highest concentrations of the medicine in the blood are typically reached about 30 minutes after taking a dose.

Q: Does Effortil have a long-term or short-term effect on the body?

Effortil has a relatively short duration of action in the body, with an elimination half-life of approximately 2.5 hours. Due to this short effect, official guidelines explain that the medicine is typically prescribed to be taken multiple times per day to support the intended therapeutic effect.

Q: Is Effortil the same type of medicine as midodrine or fludrocortisone?

According to its pharmacological classification, Effortil (Etilefrine) is categorized as a sympathomimetic agent, meaning it works on the sympathetic nervous system to raise blood pressure. While midodrine is classified as an alpha1 adrenergic agonist, fludrocortisone is classified differently as a corticosteroid. Effortil is known to act on both alpha1 and beta1 receptors.

Q: Is it common to have headaches when first starting Effortil?

Headache is listed in official product information as a common adverse reaction associated with Effortil. However, regulatory documents do not provide information on whether this side effect is more likely to occur or is specifically limited to the initial period when a person first starts taking the medicine.

Q: Is Effortil safe for older adults (seniors) to use?

Clinical research has included older adults in studies concerning the use of the medicine. Official warnings note that the medicine's use in elderly patients requires careful assessment, particularly for those who have pre-existing severe conditions affecting the heart and blood vessels.

Q: I heard Effortil can be used for orthostatic hypotension—what exactly is that?

Orthostatic hypotension is a medical term for a significant drop in blood pressure that happens when a person moves from a sitting or lying position to a standing position. According to health authority definitions, this drop must meet specific measurement criteria shortly after standing up.

Q: What is the difference between Effortil tablets and the liquid form?

Effortil is available as both tablets and oral drops (a liquid form). The oral drops are noted in product information as offering greater flexibility, allowing the dose to be adjusted based on the patient's individual condition. It is noted that the drops must always be diluted in a liquid before ingestion.

Q: Is it normal to feel dizzy if I miss a dose of Effortil?

Dizziness is listed in official product information as an uncommon adverse reaction associated with the medicine. However, official guidance regarding a missed dose describes the correct administration schedule and does not specifically state whether missing a dose can trigger dizziness.

Q: Can Effortil cause high blood pressure in people who normally have low pressure?

Effortil functions by increasing blood pressure in individuals with hypotension (low blood pressure). Official warnings state the medicine is strictly contraindicated (prohibited) for those with pre-existing high blood pressure (hypertension). Regulatory documents indicate that monitoring of blood pressure is a factor during the treatment period.

Q: What does official guidance say about the use of Effortil in adolescents?

Official prescribing information states that the medicine is generally permitted for use in adolescents who are 12 years of age and older. It is not recommended for children under 12 years. Official documents do indicate limited use with specific dosing instructions for children as young as 1 year, but this is always under strict medical supervision.

How should Effortil be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Effortil (etilefrine) must strictly follow the requirements detailed in official regulatory product labeling to maintain the medicine's integrity and ensure public safety.

Storage Conditions

Effortil must be stored at or below 30 °C (86 °F) in a dry place and be protected from light. To maintain stability, the product must remain in its original container and must not be used after the expiry date printed on the packaging. All medicine must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Effortil must be disposed of correctly. Patients are mandated to return all unused medicine to a pharmacist. It is strictly prohibited to dispose of the product by flushing it down drains or sewerage systems or including it with household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.